News

The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.

While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.

J3401 went into effect on January 1, 2024.

Paul Friedman, MD, discusses the benefits of UltraClear Laser-Coring, patient downtime, how to decide what devices to have in your clinic, and more.

SKNJCT-003 is expected to enroll up to 60 patients.

In this week’s Pointers With Portela, the 208SkinDoc reveals his 5 essential acne care tips.

Results of this study may also be indicative of oral orismilast's ability to contribute to meaningful clinical improvements, investigators noted.

The work we do as caregivers is important, and it's equally important that we take care of ourselves.

This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.

A late breaking session from Revolutionizing Atopic Dermatitis Virtual Conference analyzed the frequency and clinical meaningfulness of conjunctivitis.

Test your knowledge of psoriasis treatment options with our 5-question quiz.

Dermatology Times asked our readers to share what conferences they are looking forward to in the first quarter of 2024.

Click here to answer this week's poll.

Click here to view Dermatology Times' comprehensive list of health awareness days, months, weeks, and initiatives for 2024.

Dermatology Times is reviewing some of the most anticipated PDUFA dates of the upcoming year.

As 2023 comes to a close, Dermatology Times is taking a look back at the updates and advances from nurse practitioners and physician assistants this year.

Here is a look back at top Dermatology Times interviews with leading experts in dermatology this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in skin cancer this year.

Review Dermatology Times' top podcasts of 2023.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in atopic dermatitis this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in acne this year.

Dermatology Times is reviewing some of the newest and largest studies coming out of this year.

Catch up on Dermatology Times conference coverage from July through December of this year.

Find out what the top 10 most popular articles of 2023 were from Dermatology Times.

Dermatology Times is reviewing the biggest news in the dermatology specialty this year.

Catch up on Dermatology Times conference coverage from January through June of this year.

Catch up on coverage of FDA-approved drugs in 2023.

Dermatology Times reviews updates and news surrounding this past year's allergen of the year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in psoriasis this year.

As 2023 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.